Coxsackievirus A7 (CVA7) is a rarely detected and poorly characterized virus that belongs to the Enterovirus A species and has three strains: Parker, USSR, and 275/58. Despite a difference in pathogenicity among the three strains, they can all be typed by CVA7-specific neutralizing antibodies. CVA7 is most closely related to CVA14, CVA16, and Enterovirus 71 (EV71), and is associated with hand, foot and mouth disease (HFMD). CVA7 is neurotropic and can cause paralytic poliomyelitis. CVA7 was widely detected in the 1950s and 1960s during paralytic epidemics. A positive test result does not necessarily indicate current or recent infection as antibodies to Coxsackie species can be detected in uninfected individuals due to moderate passive exposure to infected hosts. It is, therefore, crucial that results from all Coxsackie A serologies correlate with the clinical history of the patient and all other data available to the physician. Samples collected at the early stage of infection (primarily in children) may not yield detectable antibodies. If a recent infection is suspected, a second specimen should be collected 10 to 20 days following the initial collection and tested. References: Yamayoshi S, Iizuka S, Yamashita T, Minagawa H, Mizuta K, Okamoto M, Nishimura H, Sanjoh K, Katsushima N, Itagaki T, Nagai Y, Fujii K, Koike S. Human SCARB2-dependent infection by coxsackievirus A7, A14, and A16 and enterovirus 71. J Virol. 2012 May;86(10):5686-96. doi: 10.1128/JVI.00020-12. Epub 2012 Mar 21. PMID: 22438546; PMCID: PMC3347270. Seitsonen JJ, Shakeel S, Susi P, Pandurangan AP, Sinkovits RS, Hyvönen H, Laurinmäki P, Ylä-Pelto J, Topf M, Hyypiä T, Butcher SJ. Structural analysis of coxsackievirus A7 reveals conformational changes associated with uncoating. J Virol. 2012 Jul;86(13):7207-15. doi: 10.1128/JVI.06425-11. Epub 2012 Apr 18. PMID: 22514349; PMCID: PMC3416324.
belonging to the Picornavirus family
Coxsackie B-1 Antibody (Ab) is a specific immunological marker used in the detection of previous or ongoing infections caused by the Coxsackie B-1 virus, a member of the Enterovirus genus within the Picornaviridae family. This virus is known for its role in a variety of clinical syndromes, ranging from mild febrile illnesses to more severe conditions such as myocarditis, pericarditis, and aseptic meningitis. The presence of Coxsackie B-1 Ab, particularly IgM and IgG classes, in serum samples is indicative of the immune response triggered by the body against this pathogen. IgM antibodies usually suggest a recent acute infection, appearing early in the course of the disease and declining as the infection resolves. In contrast, IgG antibodies develop later and can persist for years, indicating past exposure and possibly conferring immunity. The detection of these antibodies is crucial for epidemiological surveillance, diagnosis, and understanding the immunopathology of Coxsackie B-1 virus infections. Advanced serological assays, including enzyme-linked immunosorbent assay (ELISA) and neutralization tests, are employed for accurate and sensitive detection of Coxsackie B-1 Ab, playing a significant role in clinical diagnosis and in differentiating this infection from other enteroviral diseases with similar clinical presentations.
Coxsackie B-2 Antibody (Coxsackie B-2 Ab) is a specific immunoglobulin marker indicative of exposure to the Coxsackie B-2 virus, a member of the enterovirus family and one of the distinct serotypes within the Coxsackie B virus group. This serotype is known for its role in various clinical manifestations ranging from mild, flu-like symptoms to more severe conditions like myocarditis, pericarditis, and pancreatitis. The presence of Coxsackie B-2 antibodies, detectable through serological assays, is crucial in the diagnosis and epidemiological tracking of these infections. The immune response to Coxsackie B-2 virus typically involves the production of both IgM and IgG antibodies. IgM antibodies appear first, indicating an acute or recent infection, whereas IgG antibodies develop subsequently, denoting a past infection or a more sustained immune response. Research into the Coxsackie B-2 virus has also underscored its potential link with more chronic conditions, such as dilated cardiomyopathy and Type 1 diabetes, where it is thought to trigger autoimmune responses. The detection of Coxsackie B-2 Ab is therefore not only important for acute clinical diagnosis and management but also for understanding the long-term pathophysiological impacts of the virus, especially in cases where it may contribute to the onset or exacerbation of autoimmune conditions. The study and monitoring of Coxsackie B-2 Ab levels aid in the comprehensive understanding of the virus's behavior, immunity development in individuals, and potential public health implications.
Coxsackie B-3 antibody (Coxsackie B-3 Ab) plays a pivotal role in the immunological response to Coxsackie B-3 virus, a significant member of the Enterovirus genus within the Picornaviridae family. This virus is known for its involvement in various clinical syndromes, ranging from mild gastrointestinal and respiratory illnesses to more severe conditions like myocarditis, pericarditis, and pancreatitis. The Coxsackie B-3 Ab is a specific antibody formed in response to infection by the Coxsackie B-3 virus, and its detection is crucial for the accurate diagnosis and epidemiological study of the virus. The presence and titers of Coxsackie B-3 Ab in a patient's serum can provide valuable insights into the timing and severity of the infection. Elevated levels of these antibodies often indicate an active or recent infection and can be instrumental in distinguishing Coxsackie B-3 virus infections from other viral syndromes with similar clinical presentations. Furthermore, the study of Coxsackie B-3 Ab contributes to understanding the pathogenesis and immune response mechanisms in diseases associated with this virus, particularly in cases of viral myocarditis, where it has been implicated in the autoimmune response leading to cardiac tissue damage. Thus, Coxsackie B-3 Ab serves as a critical marker not only for diagnostic purposes but also for advancing our understanding of the immune responses and potential therapeutic targets in diseases caused by the Coxsackie B-3 virus.
Coxsackie B-4 antibody (Coxsackie B-4 Ab) is a specific immunoglobulin marker indicative of exposure to the Coxsackie B-4 virus, a member of the Enterovirus genus within the Picornaviridae family. This virus is known for its role in various human diseases, ranging from mild febrile illnesses to more severe conditions such as myocarditis, pancreatitis, and aseptic meningitis. The presence of Coxsackie B-4 Ab is particularly significant in the context of research into the etiology of type 1 diabetes mellitus; there is accumulating evidence suggesting that Coxsackie B-4 may act as a trigger in genetically predisposed individuals, potentially initiating or accelerating pancreatic beta-cell destruction. The detection of these antibodies is achieved through serological assays, which are instrumental in epidemiological studies and individual diagnosis. The antibody response to Coxsackie B-4 can be characterized by the presence of both IgM and IgG classes; IgM antibodies denote recent infection, whereas IgG antibodies can persist, indicating past exposure. This distinction is crucial for understanding the timeline of infection and the immune response. Additionally, the study of Coxsackie B-4 Ab contributes to our understanding of viral pathogenesis and host-virus interactions, offering insights into potential therapeutic targets and preventive strategies against virus-induced autoimmune diseases.
Coxsackie B-5 Antibody (Coxsackie B-5 Ab) is a specific marker used in the serological diagnosis of infections caused by the Coxsackie B-5 virus, one of the several serotypes of the Coxsackie B viruses belonging to the Enterovirus genus. The presence of Coxsackie B-5 Ab in a patient's serum is indicative of an immune response to this particular serotype, which is known for its role in a range of acute and chronic illnesses. The Coxsackie B viruses, including serotype B-5, are primarily associated with conditions such as viral meningitis, myocarditis, pericarditis, and pleurodynia. Additionally, this serotype has been implicated in more severe pathological manifestations, including pancreatitis and neonatal sepsis. The detection of Coxsackie B-5 Ab is particularly significant in epidemiological surveillance and in clinical settings where viral etiology is suspected, especially in cases presenting with cardiac or neurological symptoms. This antibody can be identified through various serological assays, providing valuable information for the diagnosis, management, and understanding of the disease progression. Moreover, studying the immune response against Coxsackie B-5, including the dynamics of antibody production and longevity, is crucial for developing effective therapeutic strategies and preventive measures against infections caused by this virulent pathogen.
Coxsackie B-6 Ab, or Coxsackie B-6 antibody, is a significant marker in the medical diagnosis and study of infections caused by the Coxsackie B-6 virus, a member of the Enterovirus genus within the Picornaviridae family. This specific antibody is part of the immune response to the Coxsackie B-6 virus, which is known for causing a spectrum of diseases, ranging from mild gastrointestinal distress to more severe conditions like myocarditis, pericarditis, and even pancreatitis. The presence of Coxsackie B-6 Ab in a patient's blood is indicative of either a current or past infection with this virus. Clinically, the detection of these antibodies is vital for the diagnosis and management of viral infections, especially in patients presenting with symptoms of viral myocarditis, a condition where the Coxsackie B-6 virus is often implicated. The testing for Coxsackie B-6 Ab involves serological assays that measure either IgM or IgG antibodies, providing insight into the stage of the infection; IgM antibodies suggest a recent or acute infection, whereas IgG antibodies indicate a past infection or a later stage of immune response. This marker is crucial not only for individual patient diagnosis and management but also for epidemiological studies in understanding the prevalence and impact of Coxsackie B-6 virus in populations. The study and monitoring of Coxsackie B-6 Ab contribute significantly to our understanding of viral pathogenesis and the immune response in viral infections, particularly those affecting the cardiac and gastrointestinal systems.
What is Coxsackie Virus – IgG? Coxsackie viruses are a group of enteroviruses that can cause a variety of illnesses, ranging from mild to serious. These viruses are divided into Group A and Group B, each associated with different clinical conditions. Group A viruses often cause hand, foot, and mouth disease, while Group B viruses can lead to viral myocarditis, pericarditis, or aseptic meningitis. The IgG antibody test for Coxsackie virus detects long-term immune response to the virus. IgG antibodies typically develop several weeks after infection and remain in the bloodstream for months or even years, indicating past exposure or infection.
Coxsackie-IgG Type A7 (IFT) detects long-lasting antibodies to Coxsackievirus A7 and is best viewed as evidence of past exposure, not proof of a current infection. Because IFT is assay-specific and enteroviruses can cross-react, use your lab’s cutoffs and clinical context. For suspected acute disease, pair serology with PCR/NAAT (throat/stool/CSF/lesion) and/or look for a fourfold rise in IgG on paired sera 2–4 weeks apart; IgM may support recent exposure but is less reliable than PCR for timing. In the absence of symptoms, elevated IgG usually needs no treatment. If symptomatic, care is typically supportive while ruling in/out other causes.
Coxsackie-IgG Type B1 (IFT) detects long-lasting antibodies to Coxsackievirus B1 and mainly indicates past exposure, not an active infection. Because IFT methods and cutoffs differ and cross-reactivity among enteroviruses can occur, rely on your lab’s ranges and your clinical picture. For suspected acute disease, pair serology with PCR/NAAT (throat/stool/CSF/lesion) and consider paired sera to look for a fourfold IgG rise over 2–4 weeks; IgM may suggest recent exposure but is less specific than PCR for timing. Coxsackie B viruses can involve the heart (myopericarditis), meninges, or pleura/pancreas—seek evaluation if symptoms fit. In the absence of symptoms, an elevated IgG usually needs no treatment.
Crab IgG reactivity marker
Elevated antibody levels can be clinically significant
Cranberry IgG reactivity marker